artemether + lumefantrine vs chloroquine + sulfadoxine-pyrimethamine

This entry describes a direct comparison between two combination antimalarial therapies used in the treatment of uncomplicated *Plasmodium falciparum* malaria. **Artemether + Lumefantrine** is an oral fixed-dose combination therapy, with artemether providing rapid parasite clearance and symptomatic relief due to its fast action and short half-life, while lumefantrine has a longer half-life and eliminates residual parasites. This combination is designed specifically to treat malaria caused by *P. falciparum*, especially in areas with resistance to older drugs like chloroquine[3]. **Chloroquine + Sulfadoxine-Pyrimethamine** combines the blood schizonticidal activity of chloroquine with the antifolate effects of sulfadoxine and pyrimethamine, which inhibit folate synthesis in the parasite. However, widespread resistance has reduced its efficacy significantly in many regions[1][2][6]. Clinical trials have shown that **artemether-lumefantrine is more effective than chloroquine plus sulfadoxine-pyrimethamine**, offering higher cure rates and faster parasite clearance times[1][2][3]. Chloroquine-based combinations are no longer recommended as first-line therapy due to high levels of resistance.

Brand names

CoartemRiametFansidar

Other names

co-artemetherALCQ+SP